Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

United States

University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

Mayo Clinic in Arizona, Scottsdale, Arizona

Arizona Clinical Research Center, Tucson, Arizona

USC / Norris Comprehensive Cancer Center, Los Angeles, California

Mayo Clinic in Florida, Jacksonville, Florida

Cleveland Clinic-Weston, Weston, Florida

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Carle Cancer Center NCI Community Oncology Research Program, Urbana, Illinois

University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa

Cancer Center of Kansas - Wichita, Wichita, Kansas

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota

University of Nebraska Medical Center, Omaha, Nebraska

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee

Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin

Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin